SABR for primary renal cell carcinoma: single-fraction or multiple-fraction?
Menée à partir de données internationales 2007-2018 portant sur 190 patients atteints d'un carcinome primitif à cellules rénales (durée médiane de suivi : 5 ans ; âge médian : 73,6 ans), cette étude évalue l'efficacité et l'innocuité à long terme de la radiochirurgie
Renal cell carcinoma accounts for about 3% of all cancers in adults, and the most frequent solid cancer type of the kidney accounts for approximately 90% of all kidney malignancies. Early detection of renal cell carcinoma has been increasing in tandem with the use of non-invasive imaging devices such as CT, MRI, and ultrasound. Although the standard treatment for early-stage renal cell carcinoma is surgical resection, a substantial number of medically inoperable cases exist due to advanced age or comorbidities. Ablative therapies, such as percutaneous radiofrequency ablation, cryotherapy, and stereotactic ablative body radiotherapy (SABR), are recommended for patients ineligible for surgery. However, clinical data on SABR for localised renal cell carcinoma have been poor, with short follow-up reports from single centres.
The Lancet Oncology , commentaire, 2021